<DOC>
	<DOCNO>NCT01744470</DOCNO>
	<brief_summary>This prospective , interventional , open label , randomize , multicenter study design determine risk/benefit ratio 50 % reduction Advagraf® daily dose , 4 month transplantation . Randomized patient stable tacrolimus daily dose require reach target tacrolimus trough level . Based Month-3 eligibility assessment , patient randomize two group ( 1:1 ) : patient 50 % reduction daily dose Advagraf® 4 month transplantation , patient keep usual dose . The benefit/risk ratio include assessment renal function , histological lesion alloreactivity CNI nephrotoxicity , safety data ( metabolic infectious disease ) .</brief_summary>
	<brief_title>Efficacy Safety Study 4-Month Post-Renal Transplant Dose Reduction Tacrolimus ( ADEQUATE )</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Age 18 et 70 year Patient accept give write informed consent Recipients first renal allograft Cadaver living transplantation living ( non HLA identical ) donor compatible ABO blood type . Absence positive DSA use Luminex® , MFI &gt; 1,000 Negative crossmatch cytotoxicity Patient without difficulty understand communicate investigator collaborator Patient entitle Health System benefit benefit . Multiple organ transplantation Recipients dual kidney transplant Previous renal allograft History transplantation Receiving graft nonheartbeating donor Patient BMI &gt; 35 Patients evidence severe liver disease , include abnormal liver profile ( AST , ALT , total bilirubin &gt; 3 time upper limit normal ) screening . Significant severe infection , active peptic ulcer and/or difficulty absorb oral drug ( active upper gastrointestinal tract malabsorption syndrome ) HIVpositive patient , active B C hepatitis Patients de novo malignancy prior transplantation , efficiently treat basal squamous cell carcinoma skin . Leucocyte count low 2500/mm3 Female patient pregnant , lactate child bear potential practicing approve method birth control . Known allergy intolerance basiliximab , tacrolimus , macrolide antibiotic , corticosteroid , mycophenolate mofetil product excipients Participation clinical trial expand access trial investigational drug within 4 week prior enrollment concomitantly study Any clinical condition , opinion investigator , would allow safe completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Renal</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>